Nervous Disorder TRIZ Cases

SNP analysis stratifies patients by severity to enable interferon-beta dosing adjustments.

Compound I resolves slow onset and adverse effect trade-offs by selectively targeting NR2B-NMDA receptors for rapid depression treatment.

Novel 6,7-disubstituted isoquinoline derivatives enhance brain distribution and provide neuroprotection.

Calcium oxide reacts with water to stabilize S-adenosyl methionine, preventing racemization and degradation during storage.

Centhaquin adrenergic agent resolves clonidine vasoconstriction and opioid tolerance via receptor modulation.

Administers small molecule combination to promote remyelination without cell transplantation risks.

Jingzhaotoxin-V peptide analog blocks NaV1.7 channels while avoiding off-target effects on cardiac and skeletal muscle excitability.

Novel Aβ mutein oligomers target pathological epitopes with high specificity.

Segmenting NSAIDs and triptans into separate tablet layers prevents gel matrix formation that retards dissolution, ensuring immediate pain relief.

Humanized monoclonal antibodies neutralize IL-17 via high-affinity binding to reduce dosing frequency while minimizing immune response against the antibody.

Monovalent binding entities link therapeutic payloads to blood brain barrier receptors, reducing miss-sorting and degradation within endothelial cells.

Bicyclic amide peptide mimetics enhance NMDA receptor specificity and potency by forming hydrogen bonds with key amino acids at the glycine binding site.

Staggered morning dopamine agonist and evening antidepressant dosing reduces insulin resistance while treating depression.

Lactoferrin increases neuron density and survival to prevent intestinal dysfunctions.

GDF-8 antagonist antibodies block catabolic signals to treat muscle-wasting diseases like ALS and improve bone density in degenerative disorders.

Catalytically inactive clostridial neurotoxins treat pain and inflammatory disorders by retaining neuron-targeting capabilities while removing proteolytic activity.

Chimeric peptides activate opioid and NPFF receptors to deliver central analgesia.

Glutamic acid residues in peptide amphiphiles generate electrostatic repulsion to disperse nanofibers and increase epitope surface display.

A dicarboxylic acid compound inhibits amyloid beta production and attenuates tau protein signaling pathways.

Ganoderma immunomodulatory proteins promote neurite outgrowth to treat neurological disorders caused by neural circuit damage.

Adult stem cell compositions reduce headache frequency and severity by replacing transient pharmacological inhibition with durable tissue regeneration.

Lactoferrin derivatives regulate glycosaminoglycan activity to address functional imbalances in biological systems.

Small molecule compounds inhibit STING signaling to treat autoinflammatory disorders and cancer.

Tri-drug composition replaces antipsychotics to reduce tardive dyskinesia risk while maintaining symptom control.

Ester intermediates cross membranes to restore glutathione, reducing pain and enzyme levels in pancreatitis.

Human monoclonal antibodies bind interferon gamma to reduce autoimmune damage and inflammation.

1,3-propanedisulfonic acid mediates amyloid deposit dissolution while maintaining renal and gastrointestinal tolerance through optimized dosage.

Segmented dual PI3K delta and gamma inhibitors reduce cardiac toxicity while maintaining immune modulation efficacy.

Engineered beta-sheet polypeptides target CD98hc and TfR receptors to transport therapeutic agents across the blood-brain barrier.

BHA prevents degradation of diclofenac and thiocolchicoside, replacing conventional antioxidants that cause instability.

Chromatography purification of recombinant arylsulfatase A enables efficient endocytosis via the mannose-6-phosphate receptor pathway.

Dual heterocyclic antagonists block A2A and A2B receptors, restoring anti-tumor immune responses against cancers with high receptor expression.

Modified progranulin variants resist cleavage to maintain stability and improve delivery across the blood-brain barrier.

Optimized CDR sequences enhance in vivo efficacy against acute coronary syndrome plaque progression.

Cyclic dietary intervention segments treatment phases to boost mood while managing protocol complexity and compliance challenges.

Human-derived monoclonal antibodies bind dipeptide repeat proteins to address disease progression in frontotemporal lobar degeneration.

Formula I compounds target S1P5 receptors via segmentation and parameter changes, addressing specificity bottlenecks in current therapies.

Segmented SNP markers resolve the contradiction between general stroke risk assessment and personalized prediction of statin response variability.

Affinity purification extracts HMB HEX and OCT ligands from hippocampal extracts to activate PPARα and restore calcium entry for dementia treatment.

Segmented flavor supplements maintain taste during prolonged chewing to improve API absorption and reduce overdosing risks.

Aminopyridines block potassium channels to treat sensorimotor impairments, extending the therapeutic window beyond acute tPA limits.

Administering compounds that reduce succinate or inhibit dehydrogenase to suppress microglial activation and protect neurons from damage.

TAJ antagonists overcome myelin-induced inhibition to enhance axon regeneration and neuronal survival.

Polypeptides with immunoglobulin single variable domains bind CX3CR1 receptors to block fractalkine interactions.